Mechanisms of mitoxantrone in multiple sclerosis--what is known?

J Neurol Sci. 2004 Aug 15;223(1):25-7. doi: 10.1016/j.jns.2004.04.015.

Abstract

The recent publication of the MIMS-study (Mitoxantrone In Multiple Sclerosis) and the approval of several health authorities support the use of mitoxantrone in patients with active relapsing-remitting or secondary progressive multiple sclerosis. This review provides information on data thus far present on the putative mechanisms of action of mitoxantrone in the immunopathogenesis of this disabling disease.

Publication types

  • Review

MeSH terms

  • Antigen-Presenting Cells / drug effects
  • Antigen-Presenting Cells / immunology
  • Apoptosis / drug effects
  • Apoptosis / immunology
  • Cytokines / drug effects
  • Cytokines / immunology
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy / methods*
  • Immunotherapy / trends
  • Mitoxantrone / pharmacology*
  • Mitoxantrone / therapeutic use
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / physiopathology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Cytokines
  • Immunosuppressive Agents
  • Mitoxantrone